Dr. Satinder Kaur is a senior Oncologist at Max Hospital, with deep expertise in the medical management of cancer across multiple tumour types. With over 15 years of oncology practice, Dr. Kaur is recognised for experience in chemotherapy, targeted therapy, immunotherapy protocols, and the management of treatment-related complications. Trained at India’s premier cancer institutions and with international exposure to evidence-based oncology practice, Dr. Kaur brings both technical skill and compassionate patient-centred care to complex oncology cases. A growing number of patients from Kazakhstan, Uzbekistan, and Russia seek cancer treatment at Max Hospital, drawn by 5-year survival rates matching European centres, access to the same immunotherapy agents used globally, and costs 60–70% lower than in Germany or Turkey. MediKaya Healthcare coordinates all Russian-language consultation, visa support, and accommodation for CIS cancer patients.

Experience Overview

• Director – Surgical Oncology (Gynae & Robotic Surgery) at Max Super Speciality Hospital, Vaishali.
• Director – Surgical Oncology (Gynae & Robotic Surgery) at Max Multi Speciality Hospital, Noida.
• Director – Gynecological Oncology at Dharamshila Narayana Superspeciality Hospital, Vasundhara Enclave, Delhi (2013 – 2024).
•  Expertise in minimally invasive robotic surgeries for gynecological malignancies.
• Recognition: Known for delivering innovative and compassionate care in the field of gynecological oncology.

Conditions Treated

Dr. Satinder Kaur specialises in the diagnosis and management of:

• Breast Cancer Treatment
• Lung Cancer Management
• Colorectal & Gastrointestinal Cancer
• Head & Neck Cancer
• Haematological Cancers (Leukaemia, Lymphoma)
• Prostate Cancer
• Cervical & Gynaecological Cancer
• Thyroid Cancer
• Chemotherapy Administration & Management
• Immunotherapy & Targeted Therapy

Why CIS Patients Choose Dr. Satinder Kaur?

Patients from Kazakhstan, Uzbekistan, Russia and across the CIS region choose Dr. Satinder Kaur at Max Hospital because:

India’s top cancer hospitals achieve 5-year survival rates of 80%+ for breast cancer — significantly above the 43% average in Russia and 60–65% in Kazakhstan. Patients access the same treatments available in Germany and the USA (proton therapy, immunotherapy, CAR-T cell therapy) at 60–70% lower cost. Waiting time for oncology consultation in India: 48–72 hours. In Kazakhstan: 3–6 months.

Through MediKaya Healthcare, all international patients from CIS countries receive dedicated Russian-speaking coordination from the moment of first inquiry through to post-treatment follow-up. Dr. Kaur’s team at Max Hospital is experienced in treating international patients and ensures all communication, medical reports, and treatment plans are clearly explained in Russian.

Professional Memberships

• Past Executive Committee Member, Association of Gynecologic Oncologists of India (AGOI)
• Founder Secretary, North Delhi Gynae Forum (2013-2015)
• Member, International Gynecologic Cancer Society (IGCS)
• Member, European Society of Gynecological Oncology (ESGO)
• Member, Indian Association of Gynecological Endoscopists (IAGE)
• Member, Federation of Obstetricians and Gynecologists Society of India (FOGSI)Awards
• Bharat Jyoti Award for work in the field of Female Cancers by India International Friendship Society (2012)
• Women of Substance Award by Sashakt Nari Parishad (2019)
• Asia GCC Iconic Healthcare Leader Award in Gynecological Cancers (2021)Specialty Interests
• Minimal Access Surgery in Gynecological Cancer (Laparoscopy and Robotic Surgery)
• Surgery in Gynecological Cancer for Ovary, Uterus, Cervix, Vulva, and Vagina
• Complicated Recurrent Surgery
• Cytoreductive Surgery and HIPEC in Ovarian Cancer
• Prevention of Gynecological Cancers
• Oncofertility

Languages Spoken

• English
• Hindi
• Punjabi

Frequently Asked Questions

Q: Is cancer treatment in India safe for international patients?

A: Yes. JCI-accredited hospitals with dedicated international oncology teams, Russian-speaking coordinators, and 24-hour patient support. Hospitals like BLK-Max, Medanta, and Max have treated thousands of CIS cancer patients with documented outcomes.

Q: How does chemotherapy cost in India compare to Kazakhstan?

A: Chemotherapy in India costs 50–70% less than in Kazakhstan’s private hospitals. A full course of carboplatin-paclitaxel chemotherapy in India is approximately $800–$1,500 per cycle vs $2,500–$4,000 per cycle privately in Kazakhstan.

Q: Can I get immunotherapy in India? Is it available?

A: Yes. Immunotherapy drugs including pembrolizumab (Keytruda), nivolumab (Opdivo), and others are available at major Indian hospitals. Generic versions approved by Indian regulators cost 80% less than branded versions in CIS countries.

Q: How do I get a second opinion from an Indian oncologist before travelling?

A: Send your biopsy reports, PET-CT or CT scans, histopathology reports, and current treatment plan to MediKaya Healthcare via WhatsApp or email. An Indian oncologist will review and provide a second opinion report within 48 hours — free of charge.

Q: Can a patient continue chemotherapy started in Kazakhstan in India?

A: Yes, in most cases. Indian oncologists review the existing protocol and either continue it or recommend modifications. All communication with your Kazakhstan oncologist can be coordinated by MediKaya Healthcare.